Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Lineage Cell Therapeutics, Inc.

< Previous 1 2 3 Next >
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at 2023 AAPS National Biotechnology Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.